Member Info for MrJinx

Drutor, yes there is a world where the transfer doesn’t work. People are bailing that is for sure. Usual ramping crew are silent, as ever, during these sell offs.

12 MONTHS…!!!??!??!? wtf?

So, when does this self imposed clinical hold due to the Made transfer become worrisome? There’s been a virtual news blackout since the transfer supposedly started, which by itself is really poor management. In fact, it’s absolutely absurd!

When I recall the qualifying process runs pre-Ind and then the improved process to prevent the splicing of the Lentivirus, we were RNS’d at regular intervals.

Chucky doesn’t do himself any favours, does he? I’m as optimistic as the next guy but you’re right Losta, what a plum.

Oh that’s right Pumpky. I forgot your trading skills compare with Warren Buffet 🤣

And I very much doubt your claimed £10k profit (from memory) allows you a life of indolence. 🤪

Is that day release Pumpky? You get no bills and all your meals free in institutional care anyway. I’m surprised the nurses let you near the internet though.

Pumpky being shy…he meant to say ‘down 30% since Feb 9th’. Go go Super 🍅

1-4-1…no gaps. Did you not read it properly? 🤣

“ subject to sufficient preclinical or Phase I clinical trials data”

‘Preclinical’!!!! If your version of ‘facts’ is correct, why would Estonia accept pre-clinical treatments? Yer numpty 🤭

1-4-1, you’ve already been told this but Estonia has effectively all to do with the FDA. Estonia may use data from the Phase 1 trial to allow access to the ‘exemption pathway’ but it requires absolutely zero permission from the FDA. It even states in the last sentence that the Estonia scheme can run ‘alongside’ the phase 1 trial and even complement the data of the phase 1 trial. Tell me where it says the FDA have a say…

RNS 23rd Sept 2025;

“The hospital exemption pathway, as amended by the Estonian government in April 2025, permits the use of certain advanced therapy medicinal products ("ATMPs") that have not yet been authorized for commercial marketing to treat an unlimited number of patients, subject to sufficient preclinical or Phase I clinical trials data. The scheme also allows innovators to apply for reimbursement of treatment costs through the Estonian National Health Fund. This framework offers Hemogenyx Pharmaceuticals the opportunity to generate early revenue from HG-CT-1 while simultaneously expanding the body of real-world clinical data to complement its ongoing Phase I trial.”

1-4-1, I doff my cap to you mate. No matter how many times you’re made to look a complete gonad, you come back for more. DEFRA 🤣🤣🤣🤣

I once asked Haywain the specific question of taking samples of patients in Estonia, transporting it back to the US for modification, and then flying back to the patient in Estonia for administering. He did say it was possible but not likely, so the partnership with Cellin (?) would be a full production partnership

Why would ‘ANY death bring into question durability’? Hemo are trialling at half the dose they themselves feel is the optimum therapeutic dose, and this stage chiefly is for safety and secondary for efficacy. I’m not dismissing the importance of whether a patient is still alive or not, but if P1 has died, however sad, that still doesn’t bring any particular focus on durability. Now, if P3 dies, that’s more of a worry. That treatment was RNS’d as showing complete remission, whereas the RNS’ for the first two weren’t that specific. So for P3, even at half dose, it eliminated all leukaemic blasts. Therefore, they’re at the very starting position after treatment, that Hemo will be hoping for after a full dose, for future trial participants. If P3 subsequently dies, that’s more of most definitely will do as you say, ‘question durability, particularly at the lower dose’. The caveat to all this is that we don’t know the demographic that P3 belongs to. Because Hemo needed FDA permission to treat this particular patient, does that indicate the possibility that p3 was an adolescent? From reading Haywains posts over the years which indicated youth responded more favourably to immunotherapy, I believe they were. Anyway, what I’m saying is, I agree with your position, but only with P3.

Maybe if ‘T’ in HG -CT1 stood for tomatoes 🍅, Pumpky would be better informed.

😂

Lol…CheckThicky getting his bloomers in a twist again. What the heck has your post got to do with clarification on when an RNS is deemed appropriate for the passing of a patient? Where have I intimated that I think a patient has died? Where have I stated the trials aren’t going well? Yer numpty.

I read the guidelines that if a death occurs and it’s ‘suspected’ to be related to the treatment, then the trial is suspended for investigations, and then an RNS should be issued.

If P1 died after say 8-10 months, and there was no dose limiting toxicities, then it wasn’t related to HG-CT1. So I assume no RNS is required. It’s just part of normal data collection. That’s how I understand it but I’m no scientist, biologist, oncologist or doctor. I’m not even that bright an investor 🤣

If someone could clarify, that’d be grand.

‘Emmerson Resources Ltd’?

Not sure if I’m experiencing a ‘Mandela effect’. Since when has Emmerson PLC been Emmerson Resources Ltd?

@Blastoid7, I’d had my bedtime medication.

From little acorns mate. If this goes where the majority of us feel it should, your £7.5k could soon be worth £75k plus. It may splutter a bit before it gets there bonne chance!

Let it Roll, not forgetting the 333k warrants at £9 give another £3m, so that’s the whole of 2026 ££5.5m funding sorted